SAFETY DATA SHEET

Daptomycin Injection Formulation - 2nd Generation

Section 1: Identification

Product name : Daptomycin Injection Formulation - 2nd Generation

Manufacturer or supplier's details
Company : MSD
Address : 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand
Telephone : +1-908-740-4000
Emergency telephone number : +1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

Section 2: Hazard identification

GHS Classification
Specific target organ toxicity - repeated exposure (Dermal) : Category 2 (muscle, Kidney, Nervous system)

GHS label elements
Hazard pictograms : 

Signal word : Warning

Hazard statements : H373 May cause damage to organs (muscle, Kidney, Nervous system) through prolonged or repeated exposure in contact with skin.

Precautionary statements : Prevention:
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
Response:
P314 Get medical advice/ attention if you feel unwell.
Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.
SAFETY DATA SHEET

Daptomycin Injection Formulation - 2nd Generation

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>&gt;= 60 - &lt;= 100</td>
</tr>
<tr>
<td>Daptomycin</td>
<td>103060-53-3</td>
<td>&gt;= 30 - &lt; 60</td>
</tr>
</tbody>
</table>

Section 4: First-aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water.
Get medical attention if symptoms occur.

In case of eye contact: If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: May cause damage to organs through prolonged or repeated exposure in contact with skin.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during fire-fighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
### Section 6: Accidental release measures

| Personal precautions, protective equipment and emergency procedures | Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
| Environmental precautions | Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained. |
| Methods and materials for containment and cleaning up | Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements. |

### Section 7: Handling and storage

| Technical measures | Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation Advice on safe handling | Use only with adequate ventilation. Do not get on skin or clothing. Do not breathe dust, fume, gas, mist, vapours or spray. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. |
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage:
Keep in properly labelled containers.
Store in accordance with the particular national regulations.

Materials to avoid:
Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>WES-TWA</td>
<td>10 mg/m3</td>
<td>NZ OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m3</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Daptomycin</td>
<td>103060-53-3</td>
<td>TWA</td>
<td>0.4 mg/m3 (OEL 2)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures:
Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection:
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type

Hand protection material: Chemical-resistant gloves

Eye protection:
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or
SAFETY DATA SHEET

Daptomycin Injection Formulation - 2nd Generation

Skin and body protection: Work uniform or laboratory coat.

Section 9: Physical and chemical properties

Appearance: lyophilised cake
Colour: light brown
Odour: No data available
Odour Threshold: No data available
pH: 6.5 - 7.3 (as aqueous solution)
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: Not applicable
Evaporation rate: No data available
Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapour pressure: No data available
Relative vapour density: No data available
Relative density: No data available
Density: No data available
Solubility(ies)
Water solubility: No data available
Partition coefficient: n-octanol/water: Not applicable
Auto-ignition temperature: No data available
Decomposition temperature: No data available
Viscosity
SAFETY DATA SHEET

Daptomycin Injection Formulation - 2nd Generation

Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Particle size : No data available

Section 10: Stability and reactivity
Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid : Heat, flames and sparks. Avoid dust formation.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

Section 11: Toxicological information
Exposure routes : Inhalation
                    Skin contact
                    Ingestion
                    Eye contact

Acute toxicity
Not classified based on available information.

Components:
Sucrose:
Acute oral toxicity : LD50 (Rat): 29,700 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:
Daptomycin:
Species : Rabbit
Result : Mild skin irritation

Serious eye damage/eye irritation
Not classified based on available information.
Components:

Daptomycin:
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Chronic toxicity

Germ cell mutagenicity
Not classified based on available information.

Components:

Sucrose:
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
Result: negative

Daptomycin:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: Chromosome aberration test in vitro
Result: negative
Test Type: In vitro mammalian cell gene mutation test
Test system: mouse lymphoma cells
Result: negative
Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: negative
Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative
Test Type: Unscheduled DNA synthesis (UDS) test with mammalian liver cells in vivo
Species: Hamster
Application Route: Intraperitoneal injection
Result: negative
Carcinogenicity
Not classified based on available information.

Reproductive toxicity
Not classified based on available information.

Components:

Daptomycin:
Effects on fertility: Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Intravenous injection
Fertility: NOAEL: 150 mg/kg body weight
Result: No effects on fertility

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rat
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 75 mg/kg body weight
Result: No significant adverse effects were reported

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 75 mg/kg body weight
Result: No significant adverse effects were reported

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs (muscle, Kidney, Nervous system) through prolonged or repeated exposure in contact with skin.

Components:

Daptomycin:
Target Organs: muscle, Kidney, Nervous system
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Daptomycin:
Species: Dog
NOAEL: 20 mg/kg
LOAEL: 40 mg/kg
Application Route: Intravenous
Exposure time: 3 Months
Target Organs: Skeletal muscle
Species: Monkey
NOAEL: 10 mg/kg
Application Route: Intravenous
Exposure time: 1 Months
Remarks: No significant adverse effects were reported

Species: Dog
Application Route: Intravenous
Exposure time: 28 Days
Target Organs: Skeletal muscle, Nervous system
Symptoms: muscle twitching

Species: Juvenile dog
LOAEL: 50 mg/kg
Application Route: Intravenous
Exposure time: 28 Days
Target Organs: Skeletal muscle, Nervous system

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Daptomycin:
General Information: Symptoms: Rash, Diarrhoea, vaginitis

Section 12: Ecological information

Ecotoxicity
No data available

Persistence and degradability
No data available

Bioaccumulative potential

Components:

Sucrose:
Partition coefficient: n-octanol/water: Pow: < 1

Mobility in soil
No data available

Other adverse effects
No data available
Section 13: Disposal considerations

Disposal methods
- Waste from residues: Dispose of in accordance with local regulations.
- Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations
- UNRTDG: Not regulated as a dangerous good
- IATA-DGR: Not regulated as a dangerous good
- IMDG-Code: Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
- Not applicable for product as supplied.

National Regulations
- NZS 5433: Not regulated as a dangerous good

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number
- HSR100425 Pharmaceutical Active Ingredients Group Standard 2017

HSW Controls
- Certified handler certificate not required.
- Tracking hazardous substance not required.
- Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:
- AICS: not determined
- DSL: not determined
- IECSC: not determined
Further information

Date format: dd.mm.yyyy

Full text of other abbreviations
ACGIH: USA. ACGIH Threshold Limit Values (TLV)
NZ OEL: New Zealand. Workplace Exposure Standards for Atmospheric Contaminants
ACGIH / TWA: 8-hour, time-weighted average
NZ OEL / WES-TWA: Workplace Exposure Standard - Time Weighted average

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS mate-
Material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NZ / EN